A round of Series A financing has pulled in over $4 million for San Antonio-based bioAffinity Technologies, maker of the CyPath early-stage lung cancer test. The money will be used to commercialize bioAffinity's lung cancer test and further develop tests and therapeutics for cancer, said company President and CEO Maria Zannes.
BioAffinity secures $4M-plus in financing round
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.